InterMune posts Q4 profit, ends ovarian cancer trial (Chronic Hepatitis C)

InterMune posts Q4 profit, ends ovarian cancer trial
bizjournals.com via Yahoo! Finance - Feb 02 2:37 PM
InterMune Inc. said Thursday it had a profit of $59.7 million in the fourth quarter ended in December, compared with a loss of $21.8 million a year ago in the same period.Save to My Web

Defence says it lacks disclosure of witnesses as tainted-blood case begins
Canadian Press via Yahoo! News - Feb 06 2:55 PM
TORONTO (CP) - The criminal trial involving the man at the centre of the tainted-blood scandal began Monday with defence lawyers accusing the Crown of attempting to bombard the court with expert witnesses to turn the case into "a public inquiry."Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 1:04 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web